Aardvark Therapeutics Investors Face October 13 Deadline in Fraud Suit

The lawsuit, spearheaded by the Rosen Law Firm, alleges that Aardvark Therapeutics issued a registration statement and prospectus for its February 2025 initial public offering that contained materially false or misleading information. According to the complaint, the company failed to disclose that ARD-101 was less safe than publicly represented, leading to an overstatement of the drug’s clinical, regulatory, and commercial viability. As these adverse facts reached the market, investors claim to have suffered significant financial losses.

Those who purchased common stock traceable to the IPO or securities during the designated class period may be entitled to compensation. While a class action has been filed, no class has been certified yet, meaning investors are not represented by counsel unless they actively retain a firm. Investors have the option to remain absent class members or participate as a lead plaintiff to help direct the litigation. The Rosen Law Firm has provided a portal for stakeholders to join the action or contact attorney Phillip Kim for further details regarding the case.